Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Net Income towards Common Stockholders (2016 - 2025)

Rein Therapeutics filings provide 10 years of Net Income towards Common Stockholders readings, the most recent being $7.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 16.6% year-over-year to $7.4 million, compared with a TTM value of -$10.6 million through Dec 2025, up 21.33%, and an annual FY2025 reading of -$9.9 million, up 26.61% over the prior year.
  • Net Income towards Common Stockholders hit $7.4 million in Q4 2025 for Rein Therapeutics, up from -$5.5 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $8.8 million in Q4 2024, with the low at -$9.0 million in Q2 2024.
  • Median Net Income towards Common Stockholders over the past 5 years was -$6.2 million (2022), compared with a mean of -$4.7 million.
  • The largest YoY upside for Net Income towards Common Stockholders was 220.99% in 2024 against a maximum downside of 380.8% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$6.8 million in 2021, then soared by 31.0% to -$4.7 million in 2022, then crashed by 55.01% to -$7.3 million in 2023, then skyrocketed by 220.99% to $8.8 million in 2024, then dropped by 16.6% to $7.4 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at $7.4 million, -$5.5 million, and -$6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.